Emilie Cornec-Le Gall

Emilie Cornec-Le Gall

Auto-generated profile, based on publicly available information

Emilie Cornec-Le Gall

Service de Néphrologie, Hémodialyse et Transplantation Rénale, Centre de référence MARHEA, Filière ORKID, CHRU de Brest, Brest, France; University of Brest, Inserm, UMR 1078, GGB, Brest, France

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in The Lancet
Verified
Journal Article
Closed access
EGEmilie Cornec-Le Gall
Emilie Cornec-Le Gall
AAAhsan Alam
Ahsan Alam
RPRonald D Perrone
Ronald D Perrone

1 June 2013 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
EGEmilie Cornec-Le Gall
Emilie Cornec-Le Gall
MAMarie-Pierre Audrézet
Marie-Pierre Audrézet
Jian-Min ChenJian-Min Chen
Jian-Min Chen
MHMaryvonne Hourmant
Maryvonne Hourmant
MMMarie-Pascale Morin
Marie-Pascale Morin
YMYannick Le Meur
Yannick Le Meur
Autosomal dominant polycystic kidney disease (ADPKD) is heterogeneous with regard to genic and allelic heterogeneity, as well as phenotypic variability. The genotype-phenotype relationship in ADPKD is not completely understood. Here, we studied 741 patients with ADPKD from 519 pedigrees in the Genkyst cohort and confirmed that renal survival associated with PKD2 mutations was approximately 20 years longer than that associated with PKD1 mutations. The median age at onset of ESRD was 58 years for PKD1 carriers and 79 years for PKD2 carriers. Regarding the allelic effect on phenotype, in contrast to previous studies, we found that the type of PKD1 mutation, but not its position, correlated strongly with renal survival. The median age at onset of ESRD was 55 years for carriers of a truncating mutation and 67 years for carriers of a nontruncating mutation. This observation allows the integration of genic and allelic effects into a single scheme, which may have prognostic value.

1 June 2016 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
BPBinu Porath
Binu Porath
VGVladimir G. Gainullin
Vladimir G. Gainullin
EGEmilie Cornec-Le Gall
Emilie Cornec-Le Gall
EDElizabeth K. Dillinger
Elizabeth K. Dillinger
CHChristina M. Heyer
Christina M. Heyer
PHPeter C. Harris
Peter C. Harris

1 March 2016 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
EGEmilie Cornec-Le Gall
Emilie Cornec-Le Gall
MAMarie-Pierre Audrézet
Marie-Pierre Audrézet
ARAnnick Rousseau
Annick Rousseau
MHMaryvonne Hourmant
Maryvonne Hourmant
EREric Renaudineau
Eric Renaudineau
YMYannick Le Meur
Yannick Le Meur
The course of autosomal dominant polycystic kidney disease (ADPKD) varies among individuals, with some reaching ESRD before 40 years of age and others never requiring RRT. In this study, we developed a prognostic model to predict renal outcomes in patients with ADPKD on the basis of genetic and clinical data. We conducted a cross-sectional study of 1341 patients from the Genkyst cohort and evaluated the influence of clinical and genetic factors on renal survival. Multivariate survival analysis identified four variables that were significantly associated with age at ESRD onset, and a scoring system from 0 to 9 was developed as follows: being male: 1 point; hypertension before 35 years of age: 2 points; first urologic event before 35 years of age: 2 points; PKD2 mutation: 0 points; nontruncating PKD1 mutation: 2 points; and truncating PKD1 mutation: 4 points. Three risk categories were subsequently defined as low risk (0–3 points), intermediate risk (4–6 points), and high risk (7–9 points) of progression to ESRD, with corresponding median ages for ESRD onset of 70.6, 56.9, and 49 years, respectively. Whereas a score ≤3 eliminates evolution to ESRD before 60 years of age with a negative predictive value of 81.4%, a score >6 forecasts ESRD onset before 60 years of age with a positive predictive value of 90.9%. This new prognostic score accurately predicts renal outcomes in patients with ADPKD and may enable the personalization of therapeutic management of ADPKD.

16 October 2017 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
EGEmilie Cornec-Le Gall
Emilie Cornec-Le Gall
VTVicente E. Torres
Vicente E. Torres
PHPeter C. Harris
Peter C. Harris
Data indicate significant phenotypic and genotypic overlap, plus a common pathogenesis, between two groups of inherited disorders, autosomal dominant polycystic kidney diseases (ADPKD), a significant cause of ESRD, and autosomal dominant polycystic liver diseases (ADPLD), which result in significant PLD with minimal PKD. Eight genes have been associated with ADPKD (PKD1 and PKD2), ADPLD (PRKCSH, SEC63, LRP5, ALG8, and SEC61B), or both (GANAB). Although genetics is only infrequently used for diagnosing these diseases and prognosing the associated outcomes, its value is beginning to be appreciated, and the genomics revolution promises more reliable and less expensive molecular diagnostic tools for these diseases. We therefore propose categorization of patients with a phenotypic and genotypic descriptor that will clarify etiology, provide prognostic information, and better describe atypical cases. In genetically defined cases, the designation would include the disease and gene names, with allelic (truncating/nontruncating) information included for PKD1. Recent data have shown that biallelic disease including at least one weak ADPKD allele is a significant cause of symptomatic, very early onset ADPKD. Including a genic (and allelic) descriptor with the disease name will provide outcome clues, guide treatment, and aid prevalence estimates.

1 May 2018 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
EGEmilie Cornec-Le Gall
Emilie Cornec-Le Gall
RORory J. Olson
Rory J. Olson
WBWhitney Besse
Whitney Besse
CHChristina M. Heyer
Christina M. Heyer
VGVladimir G. Gainullin
Vladimir G. Gainullin
PHPeter C. Harris
Peter C. Harris